Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1231P - Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

Date

16 Sep 2021

Session

ePoster Display

Presenters

James Chih-Hsin Yang

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

J.C. Yang1, S.S. Ramalingam2, T.M. Kim3, S. Kim4, G.J. Riely5, T. Mekhail6, D. Nguyen7, M.R. Garcia Campelo8, E. Felip9, L. Bazhenova10, S. Jin11, C. Griffin12, V. Bunn13, J. Lin14, E.N. Churchill15, M. Mehta11, P.A. Janne16, C. Zhou17

Author affiliations

  • 1 Department Of Medical Oncology, National Taiwan University Cancer Center, 106 - Taipei/TW
  • 2 Hematology And Medical Oncology Department, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 3 Department Of Hemato Oncology, Seoul National University Hospital, 03080 - Seoul/KR
  • 4 Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 5 Department Of Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 6 Thoracic Cancer Program, AdventHealth Orlando, Orlando/US
  • 7 Hematology-oncology, Pacific Shores Medical Group, Long Beach/US
  • 8 Dept. Medical Oncology, University Hospital A Coruña, CHUAC, A Coruña/ES
  • 9 Medical Oncology Service (lung Cancer Unit), Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 10 Moores Cancer Center, University of California San Diego, La Jolla/US
  • 11 Clinical Science, Oncology, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 12 Global Patient Safety Evaluation, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 13 Statistics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 14 Oncology Statistics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 15 Global Medical Affairs Oncology, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 16 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 17 Department Of Medical Oncology, Shanghai Pulmonary Hospital - Tongji University School of Medicine, 200433 - Shanghai/CN
More

Abstract 1231P

Background

Mobocertinib, an oral EGFR tyrosine kinase inhibitor (TKI) designed to target EGFRex20ins mutations, demonstrated clinical efficacy in 114 platinum-pretreated EGFRex20ins+ NSCLC patients (PPP) in a phase I/II study (NCT02716116). Confirmed objective responses by independent assessment were reported in 28% of patients with median duration of response of 17.5 months. Skin toxicities are commonly reported with irreversible EGFR TKIs, including skin rash, dry skin, and paronychia.

Methods

All patients received 160 mg QD mobocertinib. We report type and incidence of any-grade (gr) and gr ≥3 skin toxicity treatment-emergent adverse events (TEAEs), frequency of dose modifications (reduction, discontinuation), and management of these events.

Results

Among 114 patients in the PPP cohort, skin toxicity events were observed in 105 (92%), with gr ≥3 events in 5 patients (4%). No patients had serious events, 5 (4%) dose reduced, and 1 patient (<1%) required dose discontinuation. Median time to onset was 9 days and median time to resolution of gr 2 and gr 3 events were 9 and 5 weeks, respectively. Rash, paronychia, dry skin, and pruritus were the most commonly reported skin toxicities (>20% of patients) (Table). Proactive management included skin care and use of topical corticosteroids (43%) including hydrocortisone (12%) and antibiotics (28%), such as clindamycin (21%) and mupirocin (18%). Table: 1231P

Skin toxicity TEAEs in >10% of patients

Data cut-off: 01 November 2020 Platinum-pretreated patients N=114 n (%)
Patients with ≥1 skin event 105 (92)
Rash* 97 (85)
Rash 52 (46)
Pruritus 29 (25)
Dermatitis acneiform 22 (19)
Rash maculopapular 16 (14)
Paronychia 44 (39)
Dry skin 41 (36)
Alopecia 23 (20)

*TEAEs grouped under Rash

Conclusions

The majority of skin toxicity events were low grade, started within the first 2 weeks of treatment, and were largely managed with skin care and proactive use of topical steroids and/or antibiotics. Types of skin toxicities observed with mobocertinib are consistent with those reported with the class of EGFR TKIs, with low frequency of high-grade toxicity.

Clinical trial identification

NCT02716116; Release date: 23 March 2006.

Editorial acknowledgement

Editorial assistance was provided by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Millennium Pharmaceuticals, Inc.

Legal entity responsible for the study

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Funding

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure

J.C. Yang: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Merck Serono, MSD, Novartis, Ono Pharmaceuticals, Pfizer, Puma Pharmaceuticals, Roche/Genentech, Takeda Oncology, Yuhan Pharmaceuticals; Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Novartis; Financial Interests, Personal, Other, coordinating PI: AstraZeneca, Daiichi Sankyo, Dizal Pharmaceutical, MSD; Financial Interests, Personal, Other, Steering Committee: Bayer, Eli Lilly, Ipsen, Janssen, Merck, Novartis, Numab, Takeda Oncology. S.S. Ramalingam: Financial Interests, Personal, Other, Honoraria or Advisory Role: Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Lilly, Genentech/Roche, GlaxoSmithKline, Takeda; Financial Interests, Institutional, Other, Research Support: Amgen, Advaxis, BMS, Genmab, AstraZeneca, Takeda. T.M. Kim: Financial Interests, Personal, Other, Honoraria or advisory role: AstraZeneca, Boryung, F. Hoffmann-La Roche Ltd./Genentech Inc., Novartis, Sanofi, Takeda; Financial Interests, Personal, Other, Research funding: AstraZeneca-Korea Health Industry Development Institute. G.J. Riely: Financial Interests, Personal, Other, Travel: Merck, Sharp & Dohme; Financial Interests, Institutional, Other, Research funding: Novartis, Roche/Genentech, Millennium, GSK, Pfizer, Infinity Pharmaceuticals, ARIAD, Mirati Therapeutics, Merck. T. Mekhail: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, BMS, Lilly, Merck, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly. M.R. Garcia Campelo: Financial Interests, Personal, Other, Consulting/advisory role: Takeda, AstraZeneca, Roche, Pfizer, BMS, Boehringer Ingelheim, Pfizer, Janssen, Eli Lilly, MSD, Sanofi. E. Felip: Financial Interests, Personal, Other, Consulting/advisory role: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Guardant Health, MSD, Novartis, Pfizer, Roche, Takeda, Merck. L. Bazhenova: Financial Interests, Personal, Other, Stock and other ownership interests: Epic Sciences; Financial Interests, Personal, Other, consulting or advisory role: Neuvogen, Janssen, Daiichi Sankyo, Boehringer Ingelheim, Merck, Regeneron, Bristol Myers Squibb, Novartis; Financial Interests, Personal, Other, research funding: BeyondSpring. S. Jin: Financial Interests, Personal, Full or part-time Employment: Takeda. C. Griffin: Financial Interests, Personal, Full or part-time Employment: Takeda. V. Bunn: Financial Interests, Personal, Full or part-time Employment: Takeda. J. Lin: Financial Interests, Personal, Full or part-time Employment: Takeda. E.N. Churchill: Financial Interests, Personal, Full or part-time Employment: Takeda. M. Mehta: Financial Interests, Personal, Full or part-time Employment: Takeda. P.A. Janne: Financial Interests, Personal, Other, Consulting: Araxes Pharmaceuticals, ARIAD/Takeda, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Lilly, Loxo Oncology, Merrimack, Mirati Therapeutics, Pfizer, Roche, Novartis, Voronoi, Daiichi Sankyo, SFJ Pharmaceuticals, Biocartis; Financial Interests, Personal, Other, research support: Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Puma Biotechnology; Financial Interests, Personal, Stocks/Shares: Gatekeeper and Loxo Oncology; Financial Interests, Personal, Royalties: Dana-Farber Cancer Institute-owned patent on EGFR mutations licensed to LabCorp. C. Zhou: Financial Interests, Personal, Other, Honoraria or advisory role: Lilly China, Sanofi, BI, Roche, MSD, Qilu, Hengrui, Innovent Biologics, C-Stone, LUYE Pharma, TopAlliance Biosciences Inc., Amoy Diagnostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings